

Inflammatory Bowel Disease Medical Management - Update

Dr Neela Sundar

Consultant Gastroenterologist

Barnsley NHS Foundation Trust

Conventional treatment for IBD

- 5 ASA
- Corticosteroids
- Thiopurines

New Therapies

- Anti TNF treatment
 - Infliximab 1998 for CD & 2008 for UC
 - Adalimumab 2007 for CD & 2015 for UC
 - Golimumab 2015 for UC
- Primary and secondary treatment failures
- Adverse effects

New therapies

- Cellular Signalling
 - IL 12 & IL 23 – Ustekinumab, Rizankizumab, Mirikizumab
 - JAK inhibitors
 - intracellular tyrosine protein kinases
 - 4 members – JAK 1, JAK 2, JAK 3 and Tyrosine Kinase
 - Small molecules – rapid action
 - First IBD therapy administered orally
 - affect multiple cytokine-dependent immune pathways
 - Tofacitinib – nonselective
 - Filgotinib, Upadacitinib – JAK 1 selective

New therapies

- Leucocyte Trafficking
 - Anti Integrin - Vedolizumab
 - Sphingosine 1 Phosphate (S1P) modulators - Ozanimod

New Therapies

- Vedolizumab - humanized monoclonal antibody against $\alpha 4\beta 7$ integrin
 - UC & Crohns Disease (2015)
- Tofacitinib (2018) – JAK Inhibitor non selective
 - UC
 - Failed or intolerant to conventional therapies and Anti TNF
- Ustekinumab – Monoclonal antibody IL12 & IL 23
 - Crohns Disease (2017)
 - UC – (2020)
 - Failed conventional therapy or Anti TNF

New Therapies

- Filgotinib (2022)
 - Selective JAK1 inhibitor maximise efficacy and minimise side effects
 - UC only NOT for CD
- Ozanimod (2022)
 - S1P modulator
 - UC only
 - Conventional and Anti TNF failure

New Therapies

- Upadacitinib (2023)
 - Second generation selective JAK1 inhibitor
 - Only small molecule for UC and CD – 2023.
 - UC – failure of conventional therapy or anti TNF
 - CD – must have had previous biologics exposure.
- Risankizumab (2023)
 - Humanized monoclonal antibody
 - IL 23
 - CD only – must have previous biologics exposure

New Therapies

- Mirikizumab (2023)
 - Monoclonal antibody IL23
 - UC Only 2023
 - Unable to tolerate conventional or anti TNF
 - Lost response to anti TNF

New Therapies

Ulcerative Colitis & Crohns disease	Ulcerative Colitis ONLY	Crohns ONLY
Infliximab Adalimumab Vedolizumab Ustekinumab Upadacitinib	Mirikizumab Tofacitinib Filgotinib	Rizankizumab

Anti TNF

- Infusion reactions
- Opportunistic Infections
- Malignancies


Vedolizumab

- Nasopharyngitis
- Headache
- Jointpain
- No serious and opportunistic infections compared to Placebo
- No PML
- No increased malignancy

Ustekinumab & IL therapies

- No difference compared to placebo
 - No serious AE, serious Infections
 - No opportunistic infections
 - No malignancies

Managing potential adverse events of JAK inhibition.



Sailish Honap et al. Frontline Gastroenterol
doi:10.1136/flgastro-2023-102400



Ozanimod

- Bradycardia
- Herpes Zoster
- Upper respiratory infections

Personalising Patient Treatment – IBD MDT

- Disease duration, phenotype, extraintestinal manifestations
- Previous drug exposure & treatment response
- Comorbidities, age, gender, BMI, muscle mass
- Safety profile
- Patient preferences
- Patient risk of future complications

Thank you
Questions